Alnylam Q2 net product revenues up 43% to $306M; Vaishnaw steps down as President

ALNYLAM PHARMACEUTICALS, INC.

2023-Q2 EPS reported -$3.62 revenue$638,044,000

Net product rev $306M (+43% YoY); GAAP net loss $276M ($2.21/share), non-GAAP net loss $202M ($1.62/share).
AMVUTTRA rev $132M, ONPATTRO $91M, GIVLAARI $58M, OXLUMO $24M; total TTR growth 72% in U.S.
Reiterated 2023 guidance: combined net product rev $1.2B-$1.285B.
U.S. Attorney's Office closed ONPATTRO marketing investigation with no action.
President Akshay Vaishnaw transitions to part-time Chief Innovation Officer, effective Oct 2, 2023.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Akshay K. Vaishnaw

Chief Innovation Officer

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2023-10-02
Filed: August 3, 2023, 7:59 PM ET

On July 31, 2023, the Company and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement (the “Letter Agreement”), whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023 (the “Transition Date”).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. updated its the second quarter ended June 30, 2023 guidance (reaffirmed).

Period: the second quarter ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On August 3, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Akshay K. Vaishnaw changed role as Chief Innovation Officer at ALNYLAM PHARMACEUTICALS, INC..

Action: transitioned
Role: Chief Innovation Officer

Exact text from the filing

On July 31, 2023, the Company and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement (the “Letter Agreement”), whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023 (the “Transition Date”).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-202313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.